A post hoc analysis utilizing the FDA toxicity grading scale to assess injection site adverse events following immunization with the live attenuated Zoster Vaccine (ZVL)-Reference-Cited by-同舟云学术

A post hoc analysis utilizing the FDA toxicity grading scale to assess injection site adverse events following immunization with the live attenuated Zoster Vaccine (ZVL)

Published:2018-09-05 Issue:12 Volume:14 Page:2916-2920
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Popmihajlov Zoran¹,Pang Lei¹,Brown Elizabeth¹,Joshi Amita¹,Su Shu-Chih¹,Kaplan Susan S.¹,Willis English D.¹

Affiliation:

1. Merck Research Laboratories, Merck & Co., Inc, Kenilworth, NJ, USA

Funder

Merck

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2018.1502517

Reference18 articles.

1. Efficacy, Safety, and Tolerability of Herpes Zoster Vaccine in Persons Aged 50-59 Years

2. Zoster Vaccine: Current Status and Future Prospects

3. A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults

4. Safety of Herpes Zoster Vaccine in the Shingles Prevention Study

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative immunogenicity and safety of SpikoGen®, a recombinant SARS-CoV-2 spike protein vaccine in children and young adults: An immuno-bridging clinical trial;International Immunopharmacology;2024-01

2. Evaluating the efficacy and safety of SpikoGen®, an Advax-CpG55.2–adjuvanted severe acute respiratory syndrome coronavirus 2 spike protein vaccine: a phase 3 randomized placebo-controlled trial;Clinical Microbiology and Infection;2023-02

3. Proposing a standardized assessment of COVID-19 vaccine-associated cutaneous reactions;Journal of the American Academy of Dermatology;2023-01

4. Immunogenicity and Safety of SpikoGen, an Adjuvanted Recombinant SARS-CoV-2 Spike Protein, as a Heterologous Third Booster Dose in Kidney Transplant Patients: A Single-arm Clinical Trial;Clinical Therapeutics;2022-12

5. Safety and immunogenicity of SpikoGen®, an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations;Clinical Microbiology and Infection;2022-09